Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 for Moderate-to-severe Ulcerative Colitis
NCT03341962Phase 2Terminated
- Sponsor
- Immunic Therapeutics
- Start
- Mar 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in ulcerative colitis (UC) (8 arms), sponsored by Immunic Therapeutics. Primary endpoint: Symptomatic Remission and Endoscopic Healing at 10 weeks. Started Mar 2018; status: terminated.
02
Drugs
vidofludimus calcium
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03341962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341962.